Menu

News & Blog

Newsroom and our expert advice and guidance....

Seal of approval for software house

Seal of approval for software house
A GROWING Newcastle software house is on cloud nine after its latest software was given the thumbs up by the Government’s procurement agency.

Only three months after launching Nucleus, Datatrial is celebrating after the Crown Commercial Service (CCS) listed the software on the G-Cloud framework of the public sector’s Digital Marketplace.

Dr Emma Banks, CEO of Datatrial explained: “Being included on the Digital Marketplace [G-Cloud 10 Cloud Software] for healthcare is a huge result for Nucleus, which was only launched in March.

“This means our software is now automatically pre-qualified for sale to any part of the NHS and National Institute for Health Research (NIHR). This provides great scope for the software in the future and gives us access to a massive and important marketplace

The Digital Marketplace is a government platform for public sector organisations and sales on G-Cloud have already topped £3bn (records started in April 2012).  

To date 48% of sales (by value) and 70% (by volume) on the G-Cloud framework on the Digital Marketplace have been awarded to small and medium-sized enterprises (SMEs); and over 80% of sales (by value) were through central government with the rest from the wider public sector.

“Selling into public sector organisations such as the NHS and NIHR can be painstakingly slow and difficult for SME’s if you are not on an approved platform. This opportunity will undoubtedly accelerate our plans for Nucleus. It will also assist us to broaden our horizons and provide access to new markets because Nucleus is not limited to use in clinical research trials, it also has practical applications for collaboration, data access, compliance and project management.”

Datatrial develop software to improve the clinical research process and recently launched software ‘Nucleus’ in both the US and Europe - the company’s first new product launch in nine years following on from its leading clinical trial software nowEDC.






Back to news & blog